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Abstract
Background: Valvular heart disease, including rheumatic heart disease (RHD), is an important cause of heart disease
globally. Management of advanced disease can include surgery and other interventions to repair or replace affected
valves. This article summarises the methodology of a study that will incorporate enhanced data collection systems
to provide additional insights into treatment choice and outcome for advanced valvular disease including that due
to RHD.
Methods: An enhanced data collection system will be developed linking an existing Australian cardiac surgery registry
to more detailed baseline co-morbidity, medication, echocardiographic and hospital separation data to identify
predictors of morbidity and mortality outcome following valve surgery.
Discussion: This project aims to collect and incorporate more detailed information regarding pre and postoperative
factors and subsequent morbidity. We will use this to provide additional insights into treatment choice and outcome.
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Background
Valvular heart disease can be congenital or acquired.
Acquired disease can be either a result of aging or due
to a disease process that damages valves. Management
of valvular heart disease can involve a combination of
medication, surgical repair or valve replacement with a
mechanical or bioprosthetic valve. There were 9,276
heart valve repair or replacement procedures reported in
Australia in the year 2013–14 [1]. From a clinician and
patient perspective, the aim is to intervene at a time and
in a way that ensures the lowest possible operative com-
plications and mortality with the best short and long-
term outcome.
A particular cause of acquired valvular heart disease
is rheumatic heart disease (RHD). Whilst now rare in
high income countries [2, 3], it remains a condition of
global health importance and an important cause of
preventable heart disease. In Australia RHD particularly
affects Aboriginal and/or Torres Strait Islander peoples
(Indigenous Australians) and older non-Indigenous
Australians [4, 5].
We have previously analysed data [6] from the Australian
and New Zealand Society of Cardiac and Thoracic
Surgeons (ANZSCTS) National Cardiac Surgery Database
[7] and have identified differences in surgical management
for RHD and nonRHD valve disease and for Aboriginal
and/or Torres Strait Islander and nonIndigenous Australian
patients [5]. In addition we have been able to identify fac-
tors associated with outcomes following valve surgery for
RHD and nonRHD related valve disease [5, 6, 8].
The details of the Database have been outlined else-
where [5]. Briefly it is an Australia-wide database for the
collection and analysis of the results of cardiac surgery
that collates data from Australian hospitals regarding
patients who have undergone cardiac surgery, the type of
surgery performed, early complications and 30 day mor-
tality. In addition the Database is linked to the Australian
National Death Index [9] to assess longer term survival.
The Database commenced in 2001 with six surgical
centres and currently encompasses 28 Australian sites.
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Clinical registries such as this provide a minimum dataset
related to the patient, the procedure and outcome. As such
they are a valuable resource for informing clinical care,
quality assurance activities and for research hypothesis
generation. While the Database collects a range of pre-
operative patient demographic, co-morbidity and outcome
data it does not include prior medication use, detailed
echocardiography measurements and non-lethal complica-
tions beyond 30 days post-procedure.
The medical management of advanced valvular disease
can include anti-platelet and anti-coagulant medication,
diuretics, angiotensin-converting enzyme (ACE) inhibitors
[10], and beta blockers but it is unclear if these agents can
influence early and longer term outcomes following sur-
gery. In addition while valvular disease can be complicated
by cardioembolism (e.g., stroke) [10] the influence of such
a history prior to surgery on outcome, and how this may
influence surgical choice, remains unclear.
Existing studies highlight the importance of echocar-
diographic assessment of the severity of valve disease
and preoperative valve and heart function. Such data is
currently not collected by the existing Database, in
particular, left ventricular endsystolic (LVESD) and
enddiastolic (LVEDD) diameter and pulmonary arterial
systolic pressure (PASP).
Valve morphology has also been shown to predict out-
come for those undergoing RHD-related mitral valve
repair including the absence of deformity of the mitral
valves leaflets and mitral valve prolapse [11] and main-
tenance of anterior mitral leaflet mobility [12].
Whilst longer-term survival beyond 30 days for the
Database is determined from the National Death Index
(NDI) [9], other outcomes are currently captured only to
30 days following surgery and only for the surgical site.
Non-lethal longer term outcomes relevant to valve
surgery include bleeding and thromboembolic complica-
tions, heart failure, endocarditis and reoperation.
Thromboembolic events reported in previous studies
for follow-up to 7 years following surgery has ranged
from none [13] to 5.9% [14] and for up to 10 years, 6%
[14] to 24.7% [15] of mechanical valve replacement
recipients and 7% [16] to 25% [17] of bioprosthetic valve
recipients. Bleeding events have been reported as be-
tween 8.8% [17] and 52.6% [18]. The long term risk and
burden of heart failure following valve surgery is poorly
defined and earlier studies have demonstrated a signifi-
cant risk of subsequent endocarditis [19] .
Reporting of re-operation varies greatly. After a repaired
mitral valve, this has ranged from none at 2 years [20] to
90% at 30 years [21], from 1% [22] at 9 years for all mitral
valve replacements, 3.4% [14] at 5 years to 12.6% [23] at
25 years for mechanical valve replacement and 3.6% at
5 years [14] to 63% at 25 years [23] for bioprosthetic valve
replacements.
Table 1 Enhanced peri-operative data collection




Transitory ischaemic attack (TIA) I65-I66
Bleeding Eye: H21.00, H35.6
Digestive system: K22.11, K22.8,
K25.4, K29.00, K29.01, K29.31,
K29.41, K29.51, K29.61, K29.71,
K29.81, K29.91, K62.5, K92.0,
K92.1, K92.2
Circulatory system: I85.00, I85.01,




Haemorrhagic disorder due to
circulating anticoagulants: D68.3
I50.9, I50.0, I50.1, I51.5, I11.0, I11.9,
I13.0, I13.2
Heart failure O74.2, O75.4, I97.1, I97.8, I25.5,
O29.1, O89.1, I09.81, I27.89
Endocarditis B33.21, I01.1, I09.1, I33, I38, I39, I42.9
Cardiac surgery (including type) CABG: 0210 – 0213;
Valve repair: aortic 02QF, mitral
02QG, pulmonary 02QH, tricuspid
02QJ
Valve replacement: aortic 02RF,
mitral 02RG, pulmonary 02RH,
tricuspid 02RJ
Percutaneous/trans-catheter valve
replacement: 623, 628, 637, 634
Percutaneous valvuloplasty:
38270-01, 38270-02
Arrhythmia I44.0-9, I45.0-9, I480-9, I49.0-9,
I97.8, I47.0, J84.1, M62.8
Pacemaker and/or defibrillator
(insertion but not replacement,
removal or adjustment): 38256-00/01
38368-00, 38390-00/01/02, 38350-00,
90202-00/01/02, 38473-00/01, 38470-
00/01, 38654-00/03, 38353-00, 38393-00
Pre-operative and discharge
Medication Time period
Beta blocker Pre-operative, on discharge
ACE Inhibitors Pre-operative, on discharge
Angiotensin Receptor Blocker Pre-operative, on discharge
Diuretic Pre-operative, on discharge
Digoxin Pre-operative, on discharge
Warfarin Pre-operative, on discharge
NOAC (new oral anticoagulants) Pre-operative, on discharge
Aspirin Pre-operative, on discharge
Clopidogrel/Prasugrel/Ticagrelor Pre-operative, on discharge
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This multicentre, enhanced surveillance system there-
fore aims to collect short and longer term outcome data
to assist in predicting outcomes and providing evidence
to inform the development of guidelines to facilitate
consistent practice. Utilizing an enhanced data collection
system it will collect and incorporate more detailed
information regarding pre and postoperative factors at
Australian sites that undertake both non-RHD and
RHD-related surgery. It will use these more detailed data
to provide additional insights into treatment choice
and outcome for valve surgery in general and RHD
specifically.
Information demonstrated to be important and relevant
will be considered for future inclusion in the existing
ANZSCTS national cardiac surgery database to assist in
predicting outcomes and providing evidence to inform the
development of guidelines to facilitate consistent and
evidencebased practice in the management of valve
disease including for that relating to RHD [10].
Methods
Population and method of sampling
Four Australian cardiothoracic surgical sites with signifi-
cant RHD and non-RHD surgical caseloads representing
cases from two different Australian jurisdictions will be
included. A random subset of patients having procedures
over the preceding ten years, will be chosen from the
existing Database.
Sample size
The sample size will be based on the number required
to detect a difference in major adverse prosthesis-related
events (MAPE) between bioprosthetic and mechanical
valve replacements. MAPE will be defined as a composite
outcome of any reoperation, major bleeding, thrombo-
embolic event, or endocarditis during late follow-up [24].
A sample size of 600 patients will be recruited based on
an anticipated rate of MAPE over ten years of follow-up
of 50% for mechanical valve replacements and 35% for
bioprosthetic valve replacement [24], a ratio of mechanical
to bioprosthetic mitral valve replacements of 2:1 [5], two-
sided alpha of 0.05 and power of 80%.
Instrumentation
An enhanced baseline dataset with identical definitions
for all data points has been created to standardize data
collection. Field names and coding have been defined in
line with the existing Database data definitions. The
enhanced baseline dataset consists of data shown in
Table 1. Pre-operative history will be based on linkage
with hospital separation data and with reference to the
Massive Transfusion Registry (MTR) [25]. Medication
and echocardiography data will be ascertained from the
index hospital admission for valve surgery including
admission history for pre-operative medication, discharge
medication and linkage with imaging reporting systems.
In addition to enhanced baseline data collection the
project will identify late (more than 30 day) complica-
tions potentially associated with valve surgery. In line
with pre-surgery morbidity this will be undertaken by
using jurisdiction hospital separation data linkage for all
hospitalizations and the conditions outlined in Table 1
as well as with reference to the MTR [25]. Outcomes
will be recorded and reported according to the Guide-
lines for reporting mortality and morbidity after cardiac
valve interventions [24] with comparisons of major
morbidity between mechanical and bioprosthetic valves
made using MAPE [26].
Once ethics committee approval is obtained for all
sites for the data collection, data will be obtained from
surgeon and hospital records for the initial admission
and entered onto data collection forms. Permission to
access the MTR will be sought to identify all valve
surgery patients (≥18 years old) who have received at
least 5 units of red blood cells (RBCs) within any 4 h
time period.
Analysis plan
The data collected will be analysed using multivariable,
logistic and Cox proportional hazard models to identify
independent factors associated with the outcome previously
analysed [5, 6] and short and long term outcome. This will
be undertaken using IBM SPSS Statistics 20 (IBM, New
York, USA) and STATA Release 14 (StataCorp LP, Texas,








Left Atrial Diameter mm
Left Atrial Area cm2
Pulmonary Artery Pressure
(maximal tricuspid regurgitant




Mean Gradient Aortic and mitral valve (mmHg)
Peak Gradient Aortic valve (mmHg)
Area Aortic and mitral valve (cm2)
Pressure half time Aortic and mitral valve (ms)
Area Planimetery Mitral valve (cm2)
Jet Area Mitral valve (cm2)
Valve morphology Aortic and mitral valve
Valve abnormality Tricuspid and pulmonary valve
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USA). Missing data will be noted and assessed for potential
bias. Possible missing data could be specific echocardio-
graphic measurements not performed, which would be
missing at random and readmission occurring outside the
jurisdiction, which may be not missing at random if they
are patients from remote areas. Where the patient’s resi-
dential address is determined to be outside the jurisdiction
of the surgical site access to local hospital separation data
will be sought. Echocardiographic continuous variables will
be stratified as necessary for analysis, using acknowledged
cut off values (e.g., mild, mod, severe). The analysis will be
assessed to determine if the new data is useful for future
incorporation in the national ANZSCTS database for
ongoing prospective collection.
This study has been reported following the Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) recommendations [27].
Discussion
The development of this multicentre, enhanced surveil-
lance systems to collect enhanced baseline and longer
term morbidity data will aim to assist in predicting out-
comes and providing evidence to inform the development
of guidelines to facilitate consistent practice. Added to the
existing national cardiac surgery database (Australian and
New Zealand Society of Cardiac and Thoracic Surgeons
(ANZSCTS)) these data may assist in deciding the most
appropriate choice and timing of surgery.
Our analysis of the current database [6] has challenged
the findings of earlier studies of surgical outcome in
other settings. The finding that neither prior nor new
post-operative AF was found to be an independent pre-
dictor of survival in RHD versus non-RHD valve surgery
highlights the importance of considering these conditions
as separate entities in the setting of valve surgery [28].
Our earlier finding that poorer preoperative clinical status,
based on NYHA class, was also not independently associ-
ated with longer term survival requires further investiga-
tion with the addition of other cardiac and non-cardiac
factors that influence NYHA-measured function to assess
an independent effect on survival [6]. The addition of
medications, echocardiography results and longer-term
follow-up will also assist in strengthening the under-
standing regarding how pre-operative comorbidities and
medication use influence outcome with the ultimate aim
of enhance the timing and management of patient with
advanced valvular heart disease.
Conclusion
This article summarises the methodology of a project
that aims to collect and incorporate more detailed infor-
mation regarding pre and postoperative factors and non-
lethal outcomes at Australian sites that undertake a
significant proportion of RHD and non-RHD surgery.
We will use these more detailed data to provide additional
insights into treatment choice, timing and outcome.
Information demonstrated to be important and rele-
vant will be considered for future inclusion in an
ongoing Australia cardiac surgery registry to assist in
predicting outcomes and providing evidence to inform
the development of guidelines to facilitate consistent
and evidencebased practice in the surgical management
of valve disease.
Such data will also be integral to informing future
national and international guidelines for the manage-
ment of advanced valvular heart disease including for
RHD as part of the Australian guideline for prevention,
diagnosis and management of acute rheumatic fever and
rheumatic heart disease [10].
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